MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$161,307K
EPS
-$3.64
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
133,720
General and administrative
36,107
Total operating expenses
169,827
Loss from operations
-169,827
Interest income
9,094
Interest expense
489
Other expense, net
-85
Total other income, net
8,520
Net loss
-161,307
Basic EPS
-3.64
Diluted EPS
-3.64
Basic Average Shares
44,259,999
Diluted Average Shares
44,259,999
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$9,094K Net loss-$161,307K Total other income,net$8,520K Interest expense$489K Other expense, net-$85K Loss from operations-$169,827K Total operatingexpenses$169,827K Research and development$133,720K General andadministrative$36,107K

Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics, Inc. (KYTX)